Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CampETEC HBC for Prevention of Campylobacter Diarrhea
NCT06122870Phase 1Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in campylobacteriosis comparing CampETEC HBC with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events at 28 days and Number of Participants With Campylobacteriosis Patterns at 144 hours. Started Dec 2023; status: completed.
02
Drugs
CampETEC HBC
03
Conditions
campylobacteriosis
Beyond the preview
Go deeper on NCT06122870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122870.